Blood BMP6 Associated with Cognitive Performance and Alzheimer's Disease Diagnosis: A Longitudinal Study of Elders
Lin Sun1, Chunni Guo2, Yan Song3
1Alzheimer's Disease and Related Disorders Center, Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Insights
Lower blood Bone Morphogenetic Protein 6 (BMP6) levels are linked to Alzheimer's disease (AD) and cognitive decline. BMP6 may serve as a blood biomarker for predicting probable AD.
Area of Science:
- Neuroscience
- Biochemistry
- Gerontology
Background:
- Bone morphogenetic protein (BMP) is implicated in Alzheimer's disease (AD) pathology.
- Specific BMPs roles in AD-related cognitive decline require further elucidation.
Purpose of the Study:
- To investigate the association between blood Bone Morphogenetic Protein 6 (BMP6) levels and cognitive function in Alzheimer's disease.
- To determine if BMP6 can serve as a biomarker for predicting probable AD.
Main Methods:
- Cross-sectional and longitudinal analysis of blood BMP6 levels and cognitive function in two cohorts (SMHC and ADNI).
- Assessment of cerebrospinal fluid (CSF) tau biomarkers and APOE genotype in a subset of participants.
- Statistical analysis to determine associations and predictive capabilities.
Main Results:
- Lower blood BMP6 levels were observed in AD patients compared to controls.
- BMP6 levels positively correlated with cognitive function.
- Combined BMP6 and APOE genotype distinguished probable AD from controls.
- Blood BMP6's effect on cognition was modulated by tau pathology.
Conclusions:
- Blood BMP6 is associated with cognitive performance in Alzheimer's disease.
- BMP6 shows potential as a predictive biomarker for probable AD.
- BMP6's role in AD pathogenesis is influenced by tau and APOE status.
Background:
Bone morphogenetic protein (BMP) plays important roles in the pathology of Alzheimer's disease (AD).
Objective:
We sought blood BMP6 involved in the processes underlying cognitive decline and detected them in association with AD.
Methods:
A total of 309 participants in Shanghai Mental Health Center (SMHC) and 547 participants in Alzheimer's disease Neuroimaging Initiative (ADNI) cohort were included. Blood BMP6 and cognitive functions were measured in all subjects of both cohorts at baseline, and in 482 subjects of ADNI cohort after one year. A total of 300 subjects in ADNI cohort were detected cerebrospinal fluid (CSF) tau biomarker, and 244 received 1-year follow-up.
Results:
AD patients had lower levels of blood BMP6 compared to normal controls, and BMP6 was positively associated with cognitive functions. Longitudinal BMP6 combing with APOE genotype could distinguish probable AD from normal controls. The influence of blood BMP6 on cognition was modulated by tau pathology.
Conclusion:
Blood BMP6 was associated with cognitive performance and identified as a potential predictor for probable AD.
More Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
07:30Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
00:49The Blood-brain Barrier